-- Imricor Medical Systems (ASX:IMR) said the first sales in the US for its NorthStar 3D mapping and guidance system are expected in the second quarter after it received clearance from the US Food and Drug Administration (FDA), according to a Tuesday Australian bourse filing.
The firm believes the US opportunity is compelling in the adult electrophysiology and in pediatric settings.
It also supported the development of future commercial sites and regional expansion opportunities in the Middle East.